EVAX (Evaxion Biotech AS) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Evaxion Biotech AS's Free Cash Flow for the three months ended in Sep. 2024 was $0.00 Mil. Evaxion Biotech AS's Revenue for the three months ended in Sep. 2024 was $3.02 Mil. Therefore, Evaxion Biotech AS's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Evaxion Biotech AS's current FCF Yield % is -159.90%.

The historical rank and industry rank for Evaxion Biotech AS's FCF Margin % or its related term are showing as below:

EVAX' s FCF Margin % Range Over the Past 10 Years
Min: -24353.42 Med: -24353.42 Max: -539.54
Current: -539.54

During the past 7 years, the highest FCF Margin % of Evaxion Biotech AS was -539.54%. The lowest was -24353.42%. And the median was -24353.42%.

EVAX's FCF Margin % is ranked worse than
69.98% of 1016 companies
in the Biotechnology industry
Industry Median: -140.87 vs EVAX: -539.54

Evaxion Biotech AS FCF Margin % Historical Data

The historical data trend for Evaxion Biotech AS's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS FCF Margin % Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-24,353.42

Evaxion Biotech AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Evaxion Biotech AS's FCF Margin %

For the Biotechnology subindustry, Evaxion Biotech AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion Biotech AS's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Evaxion Biotech AS FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Evaxion Biotech AS's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-17.778	/	0.073
	=	-24,353.42 %

Evaxion Biotech AS's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	0	/	3.017
	=	0.00 %

Evaxion Biotech AS FCF Margin % Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Website

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.